New Antiviral Option for CMV Prophylaxis After Kidney Transplant
(MedPage Today) -- Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported.
In a phase III...
Source: MedPage Today Surgery - Category: Surgery Source Type: news
More News: Clinical Trials | Cytomegalovirus | Kidney Transplant | Kidney Transplantation | Surgery | Transplant Surgery | Transplants | Urology & Nephrology